What is Wedbush's Forecast for argenex Q4 Earnings?

argenex SE (NASDAQ:ARGX - Free Report) - Investment analysts at Wedbush issued their Q4 2026 earnings estimates for shares of argenex in a research note issued to investors on Monday, June 16th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of $7.81 for the quarter. Wedbush currently has a "Outperform" rating and a $715.00 target price on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenex had a return on equity of 16.15% and a net margin of 40.20%.

Other equities research analysts have also recently issued reports about the company. Oppenheimer boosted their price objective on argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Sanford C. Bernstein raised shares of argenex from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. JMP Securities set a $699.00 price target on shares of argenex in a research note on Wednesday, May 14th. Wells Fargo & Company lifted their price objective on shares of argenex from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, Citigroup reissued a "buy" rating on shares of argenex in a report on Wednesday, May 21st. One equities research analyst has rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $709.18.

argenex Price Performance

Shares of NASDAQ ARGX traded up $4.23 during trading on Tuesday, reaching $542.15. 372,905 shares of the stock traded hands, compared to its average volume of 326,423. The stock has a market capitalization of $33.10 billion, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 0.97 and a beta of 0.39. argenex has a 52-week low of $379.39 and a 52-week high of $678.21. The company has a 50-day moving average of $586.40 and a 200-day moving average of $609.62.

Institutional Investors Weigh In On argenex

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of argenex by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after acquiring an additional 824,750 shares during the last quarter. Millennium Management LLC raised its stake in argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company's stock valued at $158,977,000 after purchasing an additional 204,180 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in argenex during the fourth quarter valued at approximately $91,013,000. GAMMA Investing LLC lifted its position in argenex by 53,684.9% during the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after purchasing an additional 135,286 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in argenex by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock worth $117,805,000 after buying an additional 124,271 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.